Aurobindo Pharma hits 52-week high despite 12% decline in PAT in Q4; here's why
In the January to March quarter this year, the company's revenues stood at ₹6,472.9 crore, up 11.4% as against ₹5,809.3 crore in the same period last year.
stocks to hold
May 2023
Polycab India hits 52-week high on strong Q4 results; here's what analysts say
Following a strong Q4 results, brokerage firms have revised the target price of the Polycab India stock.
